Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients
Open Access
- 25 August 2005
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 19 (10) , 1831-1834
Abstract
Fludarabine (FDR) therapy gives a response rate of about 30% in previously treated patients with Waldenström's macroglobulinemia (WM). The combination of FDR and cyclophosphamide (Cy) has been shown to be effective in chronic lymphoproliferative disorders. We administered the combination of FDR (30 mg/m2 i.v. D1–D3) and Cy (300 mg/m2 i.v. D1–D3) to 49 patients. Median age was 64 years. The median hemoglobin, albumin, beta 2 microglobulin and immunoglobulin M (IgM) levels were 9.9 g/100 ml, 39.6 g/l, 3 mg/l and 24.7 g/l, respectively. In all, 14 patients (29%) had not previously been treated. FDR/Cy was administered every 4 weeks for a median of four cycles. In all, 38 patients (77.6%) had partial responses, nine had stable disease and two had progressive disease. After a median of follow-up of 25 months, six patients relapsed and two patients developed large-cell lymphoma. The median time to treatment failure was 27 months. The main toxicity was hematological. In all, 12 patients died, four from progression, one from large-cell lymphoma, three from infection and four from a second malignancy. Two factors negatively influenced overall and event-free survival, age >65 years and IgM <40 g/l. The FDR/Cy combination, therefore, gives a high response rate in WM, even in previously treated patients with factors of poor prognosis.Keywords
This publication has 26 references indexed in Scilit:
- Survival and prognostic factors after initiation of treatment in Waldenstrom’s macroglobulinemiaAnnals of Oncology, 2003
- Prognostic factors in symptomatic Waldenstrom's macroglobulinemiaSeminars in Oncology, 2003
- Fludarabine in Waldenstrom's macroglobulinemiaSeminars in Oncology, 2003
- Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Treatment of Waldenstrom's Macroglobulinemia with the Combination of Fludarabine and CyclophosphamideLeukemia & Lymphoma, 2003
- Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 casesBritish Journal of Haematology, 2001
- Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory diseaseBlood, 2001
- Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study GroupBritish Journal of Haematology, 2001
- Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)Blood, 2001